GlobeNewswire

CP Kelco Receives Non-GMO Project Verification  for 30 CEKOL® Cellulose Gum Products

Share

ATLANTA, Oct. 01, 2018 (GLOBE NEWSWIRE) -- CP Kelco, a leading global producer of specialty hydrocolloid solutions, announced today that the following 30 CEKOL® Cellulose Gum products are Non-GMO Project (NGP) verified: 

  • CEKOL® Cellulose Gum 10000
  • CEKOL® Cellulose Gum 10000 P
  • CEKOL® Cellulose Gum 150
  • CEKOL® Cellulose Gum 150A
  • CEKOL® Cellulose Gum 2000
  • CEKOL® Cellulose Gum 2000 A
  • CEKOL® Cellulose Gum 2000 AG
  • CEKOL® Cellulose Gum 2000 AP
  • CEKOL® Cellulose Gum 2000 P
  • CEKOL® Cellulose Gum 20000
  • CEKOL® Cellulose Gum 20000 P
  • CEKOL® Cellulose Gum 30000
  • CEKOL® Cellulose Gum 30000 A
  • CEKOL® Cellulose Gum 30000 AP
  • CEKOL® Cellulose Gum 30000 B
  • CEKOL® Cellulose Gum 30000 BP
  • CEKOL® Cellulose Gum 30000 G
  • CEKOL® Cellulose Gum 4000
  • CEKOL® Cellulose Gum 4000 P
  • CEKOL® Cellulose Gum 40000
  • CEKOL® Cellulose Gum 500 T
  • CEKOL® Cellulose Gum 50000 W
  • CEKOL® Cellulose Gum 700
  • CEKOL® Cellulose Gum 700 P
  • CEKOL® Cellulose Gum HVD
  • CEKOL® Cellulose Gum LVD
  • CEKOL® Cellulose Gum 30
  • CEKOL® Cellulose Gum PRT 2000SA
  • CEKOL® Cellulose Gum PRT 225SA
  • CEKOL® Cellulose Gum PRT 35S

NGP is a nonprofit organization dedicated to building and protecting a non-GMO food supply in North America.

Cellulose gum, which is made from wood pulp and cotton, provides water-binding, thickening and emulsifying properties in a variety of food and beverage applications including dairy beverages and desserts, alternative dairy beverages, condiments, dressings, sauces, soups, and marinades amongst others.

“We take pride in our ongoing work to address our customers’ formulation challenges and opportunities,” said Victor Dean, SVP and General Manager, CMC at CP Kelco. “Offering NGP-verified CEKOL Cellulose Gums allows us to strengthen our toolbox of high-quality ingredients enabling the innovative development of foods and beverages to meet market demands.”

For the most up-to-date list of CP Kelco NGP-verified products, visit the Non-GMO Project website. To learn more about these products and how to develop or improve formulations, send an email to solutions@cpkelco.com or visit http://www.cpkelco.com/.

About CP Kelco

Headquartered in Atlanta, Georgia, USA, and part of J.M. Huber Corporation, CP Kelco is a leading producer of specialty hydrocolloids with offices and facilities across the globe. Featuring an extensive range of hydrocolloid solutions and serving over 100 countries, CP Kelco leverages its capabilities to bring concepts and ideas to real-world products in a broad range of applications. The company’s specialty ingredients touch a wide variety of consumer and household products and industrial applications, tailored to meet the needs of regional consumers. Key product lines are Gellan Gum, Pectin, Xanthan Gum, Cellulose Gum, Carrageenan, Diutan Gum and Microparticulated Whey Protein Concentrate, as well as other unique biopolymers. Visit http://www.cpkelco.com/ for more information.

CONTACT:
Nick Wilson
Office: +44 1372 365826 
Mobile: +44 7753 864301
nick.wilson@cpkelco.com

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novo Nordisk reports weight loss of 14.9% (16.9% if taken as intended) in STEP 1 trial4.6.2020 19:10:28 CESTPress release

Bagsværd, Denmark, 4 June 2020 – Novo Nordisk today announced headline results from STEP 1, a phase 3a trial in the STEP programme. STEP 1 is a 68-week randomised, double-blind, multicentre, placebo-controlled weight management trial. The trial investigated the efficacy and safety of once-weekly subcutaneous (sc) semaglutide 2.4 mg on body weight over 68 weeks compared to placebo in 1,961 adults with obesity or overweight with comorbidities, both in conjunction with lifestyle intervention. The STEP 1 trial met both primary endpoints. In all people randomised1, a statistically significant and superior reduction in body weight was achieved with sc semaglutide 2.4 mg compared to placebo after 68 weeks. People treated with sc semaglutide 2.4 mg achieved a weight loss of 14.9%, from a mean baseline body weight of 105.3 kg, compared to a 2.4% weight loss with placebo. In addition, 86.4% of those who received sc semaglutide 2.4 mg reached a weight loss of 5% or more after 68 weeks, compared t

Scandinavian Tobacco Group A/S: Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities4.6.2020 18:00:00 CESTPress release

Company Announcement No. 15/2020 Copenhagen, 4 June 2020 Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Claus Gregersen 2. Reason for the notification a) Position/title Member of the Board of Directors b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Purchase of shares c) Price(s) and volume(s) Price(s)Volume(s)98.8

Scandinavian Tobacco Group A/S: Indberetning og offentliggørelse af transaktioner udført af person med ledelsesansvar4.6.2020 18:00:00 CESTpressemeddelelse

Selskabsmeddelelse Nr. 15/2020 København, den 4. juni 2020 Indberetning og offentliggørelse af transaktioner udført af person med ledelsesansvar 1. Nærmere oplysninger om personen med ledelsesansvar/personen med nær tilknytning til denne a) Navn Claus Gregersen 2. Årsag til indberetningen a) Stilling/titel Medlem af bestyrelsen b) Første indberetning/ændring Første indberetning 3. Nærmere oplysninger om udstederen, deltageren på markedet for emissionskvoter, auktionsplatformen, auktionsholderen eller den auktionstilsynsførende a) Navn Scandinavian Tobacco Group A/S b) LEI-kode 5299003KG4JS99TRML67 4. Nærmere oplysninger om transaktionen/transaktionerne: gentages for (i) hver type instrument, (ii) hver type transaktion, (iii) hver dato og (iv) hvert sted, hvor der er udført transaktioner a) Beskrivelse af det finansielle instrument, instrumenttypen Identifikationskode Aktier DK0060696300 – STG b) Transaktionens art Køb af aktier c) Pris(er) og mængde(r) Pris(er)Mængde(r)98,8849 aktier98

Maha Energy AB (publ) Announce May Production Volumes4.6.2020 17:00:00 CESTPress release

­­­Maha Energy AB (publ) Strandvägen 5A SE-114 51 Stockholm www.mahaenergy.ca Press release Stockholm June 4, 2020 Maha Energy AB (publ) Announce May Production Volumes Production Volumes The Company's aggregate sales production for the month of May totaled 106,2481 barrels of oil and 52.765 million scf of gas for a combined average production of approximately 3,711 BOE/day2, before royalties and taxes. The month of May saw increasing gas sales at Tie as a new gas end-user started taking deliveries allowing for higher oil production. Further at both Tie and Tartaruga stations, oil production was somewhat affected due to temporary surface jet pump maintenance issues which were resolved during the month. Despite the pump issues and continuing Covid-19 movement restrictions, production and off-take volumes in Brazil remain stable. 1 Subject to minor standard industry adjustments at the time of custody transfer. 2 Barrels of oil equivalent ("BOE") conversion ratio of 6,000 scf: 1 bbl is us

Cyber Security 1 AB: CYBER1 Confirms Publication Date for the 2019 Annual Report4.6.2020 16:45:00 CESTPress release

CYBER1 Confirms Publication Date for the 2019 Annual Report London United Kingdom – 04 June 2020, Cyber Security 1 AB (Publ) (“CYBER1”), (Nasdaq:CYB1, OTCQX:CYBNY), has announced a revised publication date of the 9th of June, for the 2019 Annual Report. The change in date brings the 2019 Annual Report publication in line with the Cyber Security 1 AB 2020 AGM, scheduled for Tuesday, 30 June 2020. Shareholders and key stakeholders in the interim may refer to the full year unaudited accounts, through the Q4 2019 report available on our website: www.cyber1.com The annual report once published will be available to view on the CYBER1 website. Certified Adviser Mangold Fondkommission AB is the Company’s Certified Adviser. Telephone: +46 (0)8 5030 1550 E-mail: ca@mangold.se FOR FURTHER INFORMATION, PLEASE CONTACT: Investor Relations Contact: Tim Metcalfe / Zach Cohen CYBER1 Email: cyber1@investor-focus.co.uk ABOUT CYBER1 CYBER1 is engaged in providing cyber resilience solutions and conducts it